AdvaMed® State Policy Briefing: PFAS – Background, Basics, and State Policy

Join AdvaMed and Reed Smith experts to explore how the Supreme Court’s ACA ruling in Braidwood could shape preventive care and MedTech policy.

WASHINGTON – Today, AdvaMed, the Medtech Association, released the following statement from President and CEO Scott Whitaker on the impact the “One Big Beautiful Bill Act” will have on medtech innovation.

AdvaMed’s annual Medtech Showcase and Reception on Capitol Hill seeks to inform a core audience: the members of the Congress and their staff who enact the policies that help our member companies reach patients with their transformative medtech.

AdvaMed President and CEO Scott Whitaker testified before the U.S. Senate Finance Committee, bringing attention to the pressing issue of how tariffs could impact the medtech industry and, most importantly, the patients who depend on it. 

Emergency Briefing on Court Ruling on Tariffs and Its Impact on Medtech. Now On Demand!

WASHINGTON—AdvaMed, the Medtech Association, welcomed introduction of the bipartisan Access to Prescription Digital Therapeutics Act of 2025 (S. 1702/H.R. 3288) by U.S. Sens. Shelley Moore Capito (R-W.Va.) and Jeanne Shaheen (D-N.H.) and U.S. Reps. Kevin Hern (R-Okla.) and Mike Thompson (D-Calif.). The bill provides for Medicare and Medicaid coverage of evidence-based software applications used to prevent, manage, or treat medical conditions.

WASHINGTON—AdvaMed, the Medtech Association, welcomed introduction of the bipartisan Access to Prescription Digital Therapeutics Act of 2025 (S. 1702/H.R. 3288) by U.S. Sens. Shelley Moore Capito (R-W.Va.) and Jeanne Shaheen (D-N.H.) and U.S. Reps. Kevin Hern (R-Okla.) and Mike Thompson (D-Calif.). The bill provides for Medicare and Medicaid coverage of evidence-based software applications used to prevent, manage, or treat medical conditions.

Washington, D.C.–AdvaMed President and CEO Scott Whitaker released the following statement upon re-introduction of bipartisan legislation aimed at accelerating Medicare coverage for breakthrough medtech and diagnostics. The Ensuring Patient Access to Critical Breakthrough Products Act, introduced by Senators Todd Young (R-Ind.) and Alex Padilla (D-Calif.), allows Medicare beneficiaries with life-threatening or debilitating diseases or conditions access to groundbreaking medical innovations, designated as breakthrough devices to treat unmet needs and already authorized by the FDA.